Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

9.940 +0.240 (+2.47%)
Streaming Delayed Price Updated: 2:28 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines
Via Benzinga
Why Evolus Shares Jumped This Week
The company said it expects to turn a profit in the fourth quarter. 
Via The Motley Fool
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively. 
Via Benzinga
Why Evolus Shares Are Trading Higher Today
Evolus, Inc. (NASDAQ: EOLS) shares are trading higher after the company issued fourth-quarter and full-year 2022 and announced full-year 2023 revenue guidance. 
Via Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+... 
Via Benzinga
Recap: Evolus Q2 Earnings
  Evolus (NASDAQ:EOLS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Evolus's Earnings: A Preview
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Evolus will report an... 
Via Benzinga
Evolus's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
Upgrades 
Via Benzinga
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese stocks. 
Via Benzinga
Needham Is Bullish On This Botox Equivalent Aesthetics Company
Via Benzinga
Recap: Evolus Q4 Earnings
Evolus (NASDAQ:EOLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus missed... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga
A Preview Of Evolus's Earnings
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Evolus: Q1 Earnings Insights
Evolus (NASDAQ:EOLS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus beat estimated earnings by 6.06%,... 
Via Benzinga
Evolus's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, Evolus (NASDAQ:EOLS) posted sales of $34.66 million. Earnings were up 6.46%, but Evolus still reported an overall loss of $18.18 million... 
Via Benzinga
Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook
Evolus Inc's (NASDAQ: EOLS) Q4 FY21 sales increased 68% Y/Y to $34.7 million in line with interim results, beating the consensus of $33.99 million, driven... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 132.3% to $7.55 during Monday's regular session. The current volume of 17.0 million shares is 2307.5% of... 
Via Benzinga
41 Biggest Movers From Yesterday
Gainers Ebang International Holdings Inc. (NASDAQ: EBON) shares gained 35.4% to settle at $1.09 on Wednesday as investors weighed the Federal Reserve Reserve decision to leave... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Rani Therapeutics Hldgs (NASDAQ:RANI 
Via Benzinga
Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance
Evolus Inc (NASDAQ: EOLS) has posted interim Q4 sales of approximately $34.7 million (better than the consensus of $30.87 million), up 68% Y/Y, driven by higher... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022
Upgrades For W.P. Carey Inc (NYSE:WPC), B... 
Via Benzinga
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cara Therapeutics (NASDAQ:CARA) ... 
Via Benzinga
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Can Evolus Disrupt the Botox Market?
This small-cap stock is going after a billion-dollar market. 
Via The Motley Fool
Repeat Doses Of Evolus' Frown Lines Treatment Are Safe, With Decreasing Rates Of Adverse Events
Evolus Inc (NASDAQ: EOLS) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.